HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearchCompany Lookup
The Week

Biogen flips '26 guidance from expected decline to sales increase

With increased sales of its newer drugs compensating for declining revenues from its multiple sclerosis portfolio, Biogen finally is positioned once again for a "growth story," CEO Chris Viehbacher said Wednesday during the company's second quarter earnings call. The company has flipped its 2026 rev

By FiercePharma · Jul 30, 2026 · via FiercePharma

This is an aggregated industry headline. Read the full story at FiercePharma →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFierceBiotech ↗
J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout
Johnson & Johnson is cruising deeper into in vivo CAR-T waters, paying $785 million upfront to strike a de…
Jul 30, 2026
CMS reopens the 340B payment fight, this time with a survey in hand
The WeekBriefing
CMS reopens the 340B payment fight, this time with a survey in hand
CMS’s proposed 2027 OPPS rule would cut 340B drug reimbursement from ASP plus 6% to ASP minus 33.4%. The savin…
Jul 30, 2026
STAT+: Tracking the FDA expert review of Replimune's melanoma treatment
The WeekSTAT News ↗
STAT+: Tracking the FDA expert review of Replimune's melanoma treatment
STAT is live-blogging a meeting of FDA experts to review Replimune's experimental melanoma drug, RP1.…
Jul 30, 2026